Describes AICAR/acadesine, its chemical properties, biological activity, and known uses as a reference compound in biochemical research and pharmacological databases.

Discussed AMPK as a key energy sensor and possible target for improving glucose metabolism and treating type 2 diabetes, highlighting its central role in cellular fuel sensing and metabolic homeostasis.

AICAR enhanced the anti-growth and anti-proliferative effects of methotrexate in cancer cells, suggesting a potential synergistic role for AMPK activation in combination chemotherapy strategies.

Showed that AMPK responds to both cellular energy status and glucose availability through distinct upstream mechanisms, revealing a dual-sensing architecture that allows cells to independently monitor fuel supply and energy charge.

Described how AMPK interacts with many other signaling pathways involved in metabolism and cell function, including mTOR, autophagy regulators, and lipid-synthesis enzymes, positioning it as a master metabolic switch.

AICAR increased glucose uptake in skeletal muscle. AMPK activation was essential for this effect in muscle, confirming the kinase as the critical mediator of contraction-mimetic glucose transport.

AICAR increased GLUT4 and mitochondrial proteins in mouse muscle. PGC-1α played an important role in these effects, linking AMPK pharmacological activation to the same transcriptional coactivator pathway engaged by endurance exercise.

AICAR affected mitochondrial biogenesis in muscle cells, with nitric oxide synthase playing an important role, revealing a NOS-dependent signaling branch that connects AMPK activation to mitochondrial remodeling.

Activating the AMPK/PGC-1α pathway improved some mitochondrial defects in a mouse model of mitochondrial disease, suggesting therapeutic potential for pharmacological AMPK activation in inherited mitochondrial disorders.

AICAR improved several metabolic problems and lowered blood pressure in insulin-resistant rats, demonstrating that sustained AMPK activation can ameliorate multiple features of the metabolic syndrome simultaneously.

AICAR increased muscle glucose transport through AMPK-, ERK-, and PDK1-related signaling, uncovering parallel kinase cascades beyond the canonical AMPK pathway that contribute to contraction-mimetic glucose disposal.

AICAR prevented inflammation-related muscle wasting in experimental models, indicating that AMPK activation may counteract the catabolic signaling cascades triggered by chronic inflammatory states such as cachexia.

Updated understanding of AMPK activation, structure, signaling, and biological functions, incorporating recent cryo-EM structural data and newly identified regulatory phosphorylation sites that refine the mechanistic model of AMPK action.

Acadesine improved recovery of heart tissue after ischemia in an experimental cardiac model, providing early preclinical evidence that adenosine-regulating compounds can protect myocardium during ischemia-reperfusion injury.

Tested the safety and potential cardiac benefits of acadesine in patients undergoing coronary artery bypass surgery, marking one of the first randomized human trials to evaluate the compound in a clinical surgical setting.

Examined long-term survival after surgery and reported a possible survival benefit in certain patients who experienced post-reperfusion myocardial infarction, suggesting that acadesine's acute cardioprotective effects may translate into durable survival advantages.

Reviewed acadesine's potential to protect the heart during ischemia and cardiac surgery, synthesizing preclinical and early clinical data to evaluate the compound's therapeutic window and mechanism of adenosine regulation.

Reviewed the development, pharmacology, clinical research, and potential medical applications of acadesine (AICA riboside, ARA 100), providing a comprehensive overview of the compound's journey from bench research to clinical investigation.

Acadesine activated AMPK and caused apoptosis in B-cell chronic lymphocytic leukemia cells but not T lymphocytes, revealing a selective cytotoxic mechanism that could spare normal immune cells while targeting malignant B-cell populations.

AICAR caused cancer-cell death through mechanisms involving BIM and NOXA pro-apoptotic proteins. Some effects occurred independently of AMPK and p53, indicating that AICAR engages multiple cell-death pathways beyond canonical AMPK signaling.

Reviewed AICAR/acadesine as an AMPK activator and its potential use against hematologic cancers, summarizing preclinical evidence for selective pro-apoptotic effects in leukemia and lymphoma cell lines.

Found that AICAR and other AMPK agonists can affect mTOR and cell-cycle pathways through mechanisms that can occur independently of AMPK, challenging the assumption that all AICAR effects are mediated exclusively through AMPK activation.

Found that nucleosides can interfere with AICAR-stimulated AMPK activation in skeletal muscle and cancer cells, identifying a previously unrecognized competitive mechanism that may limit AICAR efficacy in nucleoside-rich cellular environments.

Reviewed potential benefits and major limitations of using drugs to reproduce exercise adaptations, concluding that while single-pathway agonists like AICAR can mimic specific molecular signatures, they fall short of replicating the systemic, multi-organ benefits of real physical activity.

Reviewed AMPK and nuclear-receptor pathways as possible targets for mimicking exercise and treating metabolic disease, exploring how pharmacological co-activation of AMPK with PPARδ or ERRα might more closely approximate the transcriptional response to endurance training.

Reviewed research on exercise mimetics, including AICAR, and discussed potential effects on metabolism and the brain, raising the possibility that AMPK-activating compounds could have neuroprotective and cognitive applications beyond skeletal muscle.

Explained why drugs can reproduce some exercise pathways but cannot easily reproduce the full-body effects of exercise, emphasizing the integrative, multi-tissue, and temporally dynamic nature of the exercise response that no single pharmacological agent can fully recapitulate.

Studied urinary AICAR concentrations in athletes and helped characterize normal AICAR levels for doping-control purposes, establishing population-based reference ranges that allow anti-doping authorities to flag abnormally elevated concentrations.

Proposed the AICAr-to-SAICAr ratio as an additional marker that may help identify external AICAR use, refining the analytical toolkit by leveraging the metabolic relationship between AICAR and its downstream purine-biosynthesis intermediate.

Reviewed emerging compounds that may affect muscle function and mitochondrial biogenesis and discussed their implications for sports drug testing, highlighting AICAR alongside GW501516 and other gene-doping candidates as high-priority targets for WADA-accredited laboratories.

Studied AICAR detection in post-race urine and plasma samples from horses to improve doping-control knowledge, extending anti-doping surveillance for AICAR beyond human athletics into the equine racing industry.